Shots:

• Invenra to receive $15.0M up front along with additional fees and funding to elect up to 20 additional targets in oncology & is eligible for development- regulatory- and commercial milestones along with royalties on net sales of any approved products
• Exelixis will own all Ab sequences discovered from the collaboration for uses in oncology or other disease areas & also get an option to obtain development and commercialization rights of Invenra’s internal pipeline programs in exchange for an opt-in fee
• Under the terms of the original agreement (announced on May 02- 2018)- the companies are collaborating to discover and develop mono-specific and multi-specific Abs to treat cancer by using Invenra’s Abs and B-Body platforms

| Ref: Exilixis | Image: Exilixis